Can two old drugs turn back the clock on aging in mental illness?

NCT ID NCT05838560

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of dasatinib and quercetin, two drugs that clear out aging cells, can safely slow down accelerated aging in older adults with treatment-resistant depression or schizophrenia. Forty participants aged 50 and older will take the drugs and be monitored for safety and tolerability. The goal is to see if this approach can reduce the physical health problems that often come with these mental disorders.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dasatinib and quercetin
What this could lead to: If it works, this could point toward a way to slow down aging-related health problems in people with serious mental disorders.
What could go wrong: This is a small, early-phase trial with only 40 people, so results may not apply widely. The drugs can have side effects like fluid retention or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING, PREMATURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant premature aging syndrome schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING, PREMATURE SCHIZOPHRENIA TREATMENT RESISTANT DEPRESSION

Contacts and locations

Locations

Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.